RBCG30

WikiDoc Resources for RBCG30
Articles
Most recent articles on RBCG30 Most cited articles on RBCG30 Review articles on RBCG30 Articles on RBCG30 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on RBCG30 Images of RBCG30 Photos of RBCG30 Podcasts & MP3s on RBCG30 Videos on RBCG30
Evidence Based Medicine
Cochrane Collaboration on RBCG30 Bandolier on RBCG30 TRIP on RBCG30
Clinical Trials
Ongoing Trials on RBCG30 at Clinical Trials.gov Trial results on RBCG30 Clinical Trials on RBCG30 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on RBCG30 NICE Guidance on RBCG30 NHS PRODIGY Guidance FDA on RBCG30 CDC on RBCG30
Books
Books on RBCG30
News
RBCG30 in the news Be alerted to news on RBCG30 News trends on RBCG30
Commentary
Blogs on RBCG30
Definitions
Definitions of RBCG30
Patient Resources / Community
Patient resources on RBCG30 Discussion groups on RBCG30 Patient Handouts on RBCG30 Directions to Hospitals Treating RBCG30 Risk calculators and risk factors for RBCG30
Healthcare Provider Resources
Symptoms of RBCG30 Causes & Risk Factors for RBCG30 Diagnostic studies for RBCG30 Treatment of RBCG30
Continuing Medical Education (CME)
CME Programs on RBCG30
International
RBCG30 en Espanol RBCG30 en Francais
Business
RBCG30 in the Marketplace Patents on RBCG30
Experimental / Informatics
List of terms related to RBCG30

rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA. It is a live vaccine, consisting of BCG genetically modified to produce abundant amounts of a 30kDa antigen that has been shown to produce a strong immune response in animals and humans. The vaccine entered clinical trials in 2004, but has since been withdrawn because of poor in vivo and in vitro potency.

Template:WikiDoc Sources